Showing 5331-5340 of 7761 results for "".
- EAACI News: Novel Antibody May Help Treat Melanomahttps://practicaldermatology.com/news/novel-antibody-may-help-treat-melanoma/2461775/A newly discovered antibody may benefit patients with melanoma who do not respond to current immunotherapies, according to a study presented at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI). Unlike
- EltaMD Teams Up With Bravo's Andy Cohen for Skin Cancer Awarenesshttps://practicaldermatology.com/news/eltamd-teams-up-with-bravos-andy-cohen-for-skin-cancer-awareness/2461729/EltaMD has partnered with Andy Cohen and the Melanoma Research Foundation on a social campaign aimed to ignite dialogue surrounding skin cancer, while educating consumers on the importance of skin checks for National Skin Cancer Awareness Month. As part of this initiative, and to encour
- Nielsen BioSciences, Maruho Co. Ltd. Enter License Agreement for the Treatment of Common Wartshttps://practicaldermatology.com/news/nielsen-biosciences-maruho-co-ltd-enter-license-agreement-for-the-treatment-of-common-warts/2461719/Nielsen BioSciences, Inc.</
- FDA Set to Review Ortho Derm's Triple Combo Acne Gelhttps://practicaldermatology.com/news/fda-set-to-review-ortho-derms-triple-combo-acne-gel/2461705/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Ortho Dermatologics’ investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel. The Prescription Drug User Fee Act (PDUFA) action date is set for October 20, 2023, accordin
- USPSTF Final Recommendation: There’s Not Enough Evidence to Support Skin Cancer Screening in Folks Without Symptomshttps://practicaldermatology.com/news/uspstf-final-recommendation-theres-not-enough-evidence-to-support-skin-cancer-screening-in-folks-without-symptoms/2461665/
- Rosacea Pipeline Update: Tarsus Starts Phase 2A Trial of TP-04 in PPRhttps://practicaldermatology.com/news/rosacea-pipeline-update-tarsus-starts-phase-2a-trial-of-tp-04-in-ppr/2461604/
- LEO Pharma, ICON Enter a Strategic Partnership to Propel Clinical Trial Execution within Dermatologyhttps://practicaldermatology.com/news/leo-pharma-icon-enter-a-strategic-partnership-to-propel-clinical-trial-execution-within-dermatology/2461602/LEO Pharma and
- Cetaphil Unveils Digital AI Skin Analysis Toolhttps://practicaldermatology.com/news/cetaphil-unveils-digital-ai-skin-analysis-tool/2461587/Cetaphil is launching Cetaphil AI Skin Analysis, a comprehensive skin analyzer off
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately contr
- Bio-Oil Celebrates Body Confidence Through Body Positivity Month Campaignhttps://practicaldermatology.com/news/bio-oil-celebrates-body-confidence-through-body-positivity-month-campaign/2461538/Bio-Oil is rolling out a month-long campaign in celebration of February's Body Positivity Month to encourage self-love, promote body confidence, and highlight the role that Bio-Oil plays in helping people to love their stretch marks due to pregnancy, to scars from surgical procedur